Prevention of Rh (D) Alloimmunization in Rh (D) Negative Women in
Pregnancy and after Birth of Rh (D) Positive Infant
Ľubušký M.1,2, Procházka M.1, Krejčová L.3, Větr M.1, Šantavý J.2, Kudela M.1
1Gynekologicko-porodnická klinika LF UP a FN, Olomouc, přednosta prof. MUDr. M. Kudela, CSc. 2Ústav lékařské genetiky a fetální medicíny LF UP a FN, Olomouc, přednosta prof. MUDr. J. Šantavý, CSc. 3Ministerstvo zdravotnictví ČR, oddělení péče o matku a dítě, odbor zdravotní péče a farmacie, Praha |
|
Summary:
Objective: The objective of this review was to assess the effects of antenatal anti-D immunoglobulin on
the incidence of Rhesus D alloimmunization when given to Rh-negative women without anti-D antibodies
and assess the effects of giving anti-D to Rhesus negative women, with no anti-D antibodies, who had
given birth to a Rhesus positive infant.
Design: A review article.
Setting: Department of Obstetrics and Gynecology, Department of Medical Genetics and Fetal Medicine,
University Hospital, Olomouc, Ministry of Health, Czech Republic.
Subject and Method: We searched the Cochrane Pregnancy and Childbirth Group trials register, refence
lists of relevant articles and bibliographies.
Conclusion: The risk of Rhesus D alloimmunization during or immediately after a first pregnancy is
about 1%. Administration of 100 μg (500 IU) anti-D to women in their first pregnancy can reduce this
risk to about 0.2% without, to date, any adverse effects. Anti-D, given within 72 hours after childbirth,
reduces the risk of RhD alloimmunization in Rhesus negative women who have given birth to a Rhesus
positive infant. However the evidence on the optimal dose is limited.
Key words:
anti-D, rhesus alloimmunization
|